<DOC>
	<DOCNO>NCT00472641</DOCNO>
	<brief_summary>This research study design determine replace current antipsychotic and/or mood stabilizer ziprasidone ( Geodon ) impact weight . This research conduct Geodon document effect mood . Additionally , believe Geodon effective medication overweight obese patient bipolar disorder . There approximately 25 patient enrol study .</brief_summary>
	<brief_title>Geodon Weight Loss Study Bipolar Disorders</brief_title>
	<detailed_description>22 obese three overweight BD patient ( 20 female ; 10 BD-I , 14 BD-II , 1 BD-NOS ) mean ` SD baseline body mass index ( BMI ) 31.8 ` 2.5 kg/m2 receive ZIP ( mean final dose 190 ` 92 mg/day ) mean 79.2 ` 23.2 day . Weight assess six weekly three biweekly visit . Subjects enter study diverse mood state . At baseline , 21 take second-generation antipsychotic , 7 lithium , 1 valproate , could reduced/discontinued investigator ' discretion .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Patients meet follow criterion eligible participate study : Diagnosis Bipolar Disorder Type I , Type II , NOS treat ongoing therapy atypical antipsychotic ( ) and/or mood stabilizer ( ) implicate cause weight gain ( i.e . lithium , valproate , olanzapine , risperidone , quetiapine , aripiprazole ) . Age 1865 year old Males ; nonpregnant , nonlactating female postmenopausal , surgically sterilize , use barrier method contraception negative pregnancy test Initial body mass index e 30 kg/m2 , e 27 kg/m2 demonstrate receive treatment metabolic consequence overweight ( fast total cholesterol e 200mg/dL , fast triglyceride e 250 mg/dL , fast blood glucose e 100 mg/dL ) . Stable medication regimen least one month Not hospitalize due medical psychiatric reason past year date consent . Ability understand cooperate study procedure Have sign write informed consent prior enter study Exclusion Criteria : Patients may participate study follow condition : One follow DSMIV Axis I diagnose : delirium , dementia , amnestic cognitive disorder , schizophrenia , anorexia nervosa bulimia , substance abuse dependence ( active within last month ) , abuse illicit drug ( exclude marijuana ) within past month Antisocial personality disorder Medical complication obesity diabetes , hypertension , hyperlipidemia , cardiovascular disease unless follow general medical practitioner authorize participation trial , continue follow medically make necessary adjustment concurrent antidiabetic , antihypertensive , antihyperlipidemic agent trial ; Item 10 ( Suicidal Thoughts ) MADRS great equal 4 Suicide attempt within past three month Obesity endocrine origin Seizure disorder Progressive neurologic systemic disorder ; HIV Other serious illness cardiac , hepatic ( include cirrhosis ) , renal , respiratory , neurologic , hematologic disease glaucoma Hypothyroidism hyperthyroidism unless adequately treat TSH 10 % limit normal range . Administration investigational drug within 30 day prior screen Allergy hypersensitivity ziprasidone Administration clozapine prior three month Pregnancy within past six month Patients discontinue study develop significant adverse side effect manage dosage adjustment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>